We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.125 | -2.67% | 4.55 | 4.11 | 4.99 | 4.41 | 4.35 | 4.39 | 482,311 | 16:35:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 27/10/2020 19:04 | nicebut next hopefully. | zagrosfold | |
| 27/10/2020 17:59 | Surely we'd not only pitch for this but secure funding?Posted by Oxford12 on LSE-Phase 3 prophylaxis trial?Today 16:01I wonder if this is part of the puzzle...I was researching NIHR trying to understand what the priority / urgent public heath status actually gave us as RM was very clear about this in the RNS. They will obviously whisk us through the ethics process of the trial, like they did in phase 2 (case study on the NIHR website), but could it be more? I found funding to set up a prophylaxis trial in UK care homes, funded by the Gov. it seems to be like recovery but for earlier in the illness and targeted at older, higher risk people. At the moment the NIHR have just opened a tender process for a research org to deliver the trials and a panel to decide which drugs are tested. Closing date is November and they stress rapid set up and delivery. Can you think of a better drug to take part in this trial?? This may be our phase 3 at home trial....https://www | tickboo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
